Anders Sundström (A Sundström)

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 15

Top Topics

Coronavirus Disease

Bioinformatics Analysis

Top Venues

Pharmacoepidemiology and drug safety

BMJ (Clinical research ed.)

This page only lists publications with an associated author ORCID identifier.

Publications

Sofia Attelind, Niclas Eriksson, Anders Sundström, Mia Wadelius, Pär Hallberg
Identification of risk factors for adverse drug reactions in a pharmacovigilance database. Pharmacoepidemiology and drug safety 33 (1) (2024)
Sofia Attelind, Niclas Eriksson, Anders Sundström, Mia Wadelius, Pär Hallberg
Identification of risk factors for adverse drug reactions in a pharmacovigilance database. Pharmacoepidemiology and drug safety (2024)
Sofia Attelind, Niclas Eriksson, Anders Sundström, Mia Wadelius, Pär Hallberg
Identification of risk factors for adverse drug reactions in a pharmacovigilance database. Pharmacoepidemiology and drug safety 33 (1) (2024)
Sofia Attelind, Niclas Eriksson, Anders Sundström, Mia Wadelius, Pär Hallberg
Identification of risk factors for adverse drug reactions in a pharmacovigilance database. Pharmacoepidemiology and drug safety (2024)
Karl Mikael Kälkner, Anders Sundström, Marja-Leena Nurminen, Maria Larsson, Rickard Ljung, Veronica Arthurson
Optimizing Safety Surveillance for COVID-19 Vaccines at the Swedish Medical Products Agency. Drug safety (2023)
Rickard Ljung, Yiyi Xu, Anders Sundström, Susannah Leach, Ebba Hallberg, Maria Bygdell, Maria Larsson, Veronica Arthurson, Magnus Gisslen, Rolf Gedeborg, Fredrik Nyberg
Association between SARS-CoV-2 vaccination and healthcare contacts for menstrual disturbance and bleeding in women before and after menopause: nationwide, register based cohort study. BMJ (Clinical research ed.) 381 (2023)
Sofia Attelind, Niclas Eriksson, Anders Sundström, Mia Wadelius, Pär Hallberg
Identification of risk factors for adverse drug reactions in a pharmacovigilance database. Pharmacoepidemiology and drug safety (2023)
Karl Mikael Kälkner, Anders Sundström, Marja-Leena Nurminen, Maria Larsson, Rickard Ljung, Veronica Arthurson
Optimizing Safety Surveillance for COVID-19 Vaccines at the Swedish Medical Products Agency. Drug safety (2023)
Karl Mikael Kälkner, Anders Sundström, Marja-Leena Nurminen, Maria Larsson, Rickard Ljung, Veronica Arthurson
Optimizing Safety Surveillance for COVID-19 Vaccines at the Swedish Medical Products Agency. Drug safety 46 (3) (2023)
Karl Mikael Kälkner, Anders Sundström, Marja-Leena Nurminen, Maria Larsson, Rickard Ljung, Veronica Arthurson
Optimizing Safety Surveillance for COVID-19 Vaccines at the Swedish Medical Products Agency. Drug safety 46 (3) (2023)
Karl Mikael Kälkner, Anders Sundström, Marja-Leena Nurminen, Maria Larsson, Rickard Ljung, Veronica Arthurson
Optimizing Safety Surveillance for COVID-19 Vaccines at the Swedish Medical Products Agency. Drug safety 46 (3) (2023)
Karl Mikael Kälkner, Anders Sundström, Marja-Leena Nurminen, Maria Larsson, Rickard Ljung, Veronica Arthurson
Optimizing Safety Surveillance for COVID-19 Vaccines at the Swedish Medical Products Agency. Drug safety 46 (3) (2023)
Rickard Ljung, Yiyi Xu, Anders Sundström, Susannah Leach, Ebba Hallberg, Maria Bygdell, Maria Larsson, Veronica Arthurson, Magnus Gisslen, Rolf Gedeborg, Fredrik Nyberg
Association between SARS-CoV-2 vaccination and healthcare contacts for menstrual disturbance and bleeding in women before and after menopause: nationwide, register based cohort study. BMJ (Clinical research ed.) 381 (2023)
Rickard Ljung, Yiyi Xu, Anders Sundström, Susannah Leach, Ebba Hallberg, Maria Bygdell, Maria Larsson, Veronica Arthurson, Magnus Gisslen, Rolf Gedeborg, Fredrik Nyberg
Association between SARS-CoV-2 vaccination and healthcare contacts for menstrual disturbance and bleeding in women before and after menopause: nationwide, register based cohort study. BMJ (Clinical research ed.) 381 (2023)
Karl Mikael Kälkner, Anders Sundström, Marja-Leena Nurminen, Maria Larsson, Rickard Ljung, Veronica Arthurson
Optimizing Safety Surveillance for COVID-19 Vaccines at the Swedish Medical Products Agency. Drug safety 46 (3) (2023)